Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd (NQ: ROIV )

12.08 -0.03 (-0.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roivant Sciences Ltd

< Previous 1 2 3 4 5 6 Next >
2 Supercharged Growth Stocks Billionaires Can't Stop Buying
A top hedge fund has been steadily buying these two growth stocks in 2023. 
Via The Motley Fool
If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now
Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy. 
Via Benzinga
8 Analysts Have This to Say About Roivant Sciences
Via Benzinga
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. 
Via Investor's Business Daily
3 Biotech Stocks That Analysts Are Drooling Over
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time. 
Via InvestorPlace
Vivek 'Da Vek' Ramaswamy: The 2024 Presidential Candidate Who Might Just Rap His Inauguration Speech
Donald Trump and Ron DeSantis have been the runaway favorites for the GOP nomination in the 2024 election, but there’s one candidate that has been climbing up the polls and gaining support from... 
Via Benzinga
Roivant Sciences's Return on Invested Capital Insights
Via Benzinga
Analyst Expectations for Roivant Sciences's Future
Via Benzinga
Why Shares of Roivant Sciences Rose Wednesday
The pharmaceutical company released fourth-quarter earnings. 
Via The Motley Fool
Earnings Scheduled For August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
2 Magnificient Growth Stocks I'm Buying in August
These biotech stocks could markedly outperform the broader market. 
Via The Motley Fool
3 Biotech Stocks for Getting Rich in 2023
These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist. 
Via InvestorPlace
2 Nasdaq Stocks That Could Soar This Week
BridgeBio Pharma and Roivant Sciences could make big moves this week. 
Via The Motley Fool
Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories
Benzinga 
Via Benzinga
Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover
The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed. 
Via Investor's Business Daily
Why Roivant Sciences Stock is Trading Higher Today
Roivant Sciences Ltd (NASDAQ: ROIV) released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with  
Via Benzinga
A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout
The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis. 
Via Investor's Business Daily
5 Analysts Have This to Say About Roivant Sciences
Via Benzinga
Why Shares of Roivant Sciences Jumped This Week
The company's stock benefited from another company's buyout. 
Via The Motley Fool
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY) 
Via Benzinga
Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market... 
Via Benzinga
Nasdaq, S&P 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results: Why This Analyst Rates Stocks 'Overweight' And Says 'Buy Weakness'
Via Benzinga
Why Roivant Sciences Stock Is Perking Up Today
Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock. 
Via The Motley Fool
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... 
Via Benzinga
Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission
Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old... 
Via Benzinga
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so. 
Via The Motley Fool
These 2 Growth Stocks Might Be Incredibly Undervalued Right Now
These two biopharma stocks could be poised for a major growth spurt. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.